Who is sponsoring NCT01492166?

NCT01492166 is sponsored by Novo Nordisk A/S.

What condition does NCT01492166 study?

NCT01492166 studies Diabetes, Diabetes Mellitus, Type 2.

What drugs are being tested in NCT01492166?

Interventions: biphasic human insulin 30.

What is the status of NCT01492166?

NCT01492166 is currently COMPLETED.

Last reviewed 2016-12-12 · How we verify

A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Mixtard® 30 NovoLet® as Monotherapy, or in Combination With Oral Hypoglycaemic Agent ( OHA ), in Treatment of Subjects With Type 2 Diabetes in Routine Clinical Practice

NCT01492166 COMPLETED

This study is conducted in Asia. The aim of this study is to assess the efficacy, safety and convenience of the use of Mixtard® 30 NovoLet® used alone or combined with oral hypoglycaemic agent (OHA) in the management of type 2 diabetes mellitus in an out-patient setting.

Details

Lead sponsor	Novo Nordisk A/S
Status	COMPLETED
Enrolment	1935
Start date	2006-11
Completion	2007-06

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

biphasic human insulin 30

Primary outcomes

Change in fasting blood glucose (FBG)
Change in 2-hour post prandial blood glucose
Change in HbA1c (glycosylated haemoglobin)
Change in prandial glucose increment (PGI)

Countries

Indonesia